NGAL an early biomarker for acute kidney injury

Neutrophil Gelatinase Associated Lipocalin an early biomarker for acute kidney injury.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON21935

Enrollment

700

Registered

2008-08-13

Start date

2007-09-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AKI Biomarkers

Interventions

This observational study was conducted in order to determine the ability of NGAL -an early biomarker of tubular damage- to predict the presence and development of Acute Kidney Injury (AKI) in a genera

Eligibility

Inclusion criteria

Inclusion criteria: All consequetively admitted patients on a general adult ICU

Exclusion criteria

Exclusion criteria: 1. Age under 18 2. Nefrectomy

Design outcomes

Primary

Measure	Time frame
Observational study	—

Secondary

Measure	Time frame
Observational study	—

Contacts

Public ContactHilde Geus, de

Erasmus University Medical Center Rotterdam Dept of Intensive Care, H620 PO Box 2040

h.degeus@erasmusmc.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)